AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US ...

A woman whose cancer has spread to her bones, back, pelvis and neck but has been denied a life-extending drug because she ...

AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...

In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal ...

Vaccine maker shares closed lower Thursday amid reports that Donald Trump was set to nominate vaccine critic Robert F.

"Slingshot represents an opportunity to bridge the gap between academic innovation and clinical development of a novel ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

By exploiting the genetic variation in cancer cells, an already approved cancer drug demonstrated enhanced effects against ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...